Evidence map›Paper›PMID 40269277›Full record

ArticleBone marrow transplantation2025

Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Sara Tarantino, Myriam Labopin, Robert Zeiser, Matthias Stelljes, Thomas Schroeder, Nicolaus Kröger, Wolfgang Bethge, Jakob Passweg, Martin Bornhäuser, Christoph Schmid and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sara TarantinoDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. saratarantino93@gmail.com.ORCID 0009-0007-5168-7243
Myriam LabopinEBMT Paris study office / CEREST-TC, Paris, France.
Robert ZeiserLeiter der Abteilung für Tumorimmunologie und Immunregulation Klinik für Innere Medizin, Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation, Universitätsklinikum Freiburg, Hugstetter Str, 55 79106, Freiburg, Germany.ORCID 0000-0001-6565-3393
Matthias StelljesUniversity of Muenster, Muenster, Germany.ORCID 0000-0002-9331-5145
Thomas SchroederUniversity Hospital Essen, Essen, Germany.
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-5103-9966
Wolfgang BethgeUniversitaet Tuebingen, Tuebingen, Germany.ORCID 0000-0001-6052-2618
Jakob PasswegUniversity Hospital, Hematology - Basel, Basel, Switzerland.ORCID 0000-0001-7092-3351
Martin BornhäuserUniversitaetsklinikum Dresden, Dresden, Germany.ORCID 0000-0002-5916-3029
Christoph SchmidKlinikum Augsburg- University of Augsburg, Augsburg, Germany.
Johanna TischerKlinikum Grosshadern- University of Munich, Munich, Germany.ORCID 0000-0003-1821-1976
Matthias EderHannover Medical School, Hannover, Germany.
Eolia BrissotDepartment of Hematology and Cell therapy, Saint Antoine Hospital, Paris, France.ORCID 0000-0003-4471-418X
Jordi EsteveHospital Clinic Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0002-8056-648X
Arnon NaglerHematology Division, Chaim Sheba Medical Center and Tel Aviv University, Tel-Hashomer, Ramat-Gan, Israel.
Mohamad MohtyDepartment of Hematology and Cell therapy, Saint Antoine Hospital, Paris, France.ORCID 0000-0002-7264-808X
Fabio CiceriUnit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Core-binding factor acute myeloid leukemia (CBF-AML) generally has a favorable prognosis, with allogeneic hematopoietic stem cell transplantation (allo-SCT) recommended for relapsed/ refractory (R/R) cases achieving second complete remission (CR). However, clinical outcomes remain suboptimal for patients who relapse or fail to achieve CR following induction chemotherapy. Allo-SCT in non-CR is a potential strategy for such patients, though supporting evidence in CBF-AML is limited. To assess outcomes and prognostic factors of allo-SCT in R/R CBF-AML with active disease, we conducted a retrospective analysis of 610 patients with CBF-AML in non-CR undergoing allo-SCT from 2010 to 2021 across 174 centers within the European Society for Blood and Marrow Transplantation. Graft sources included matched sibling (MSD, n = 151), unrelated (UD, n = 368), and haploidentical donors (Haplo, n = 91). Among patients, 124 had inv(16), and 486 had t(8;21). Two-year overall survival (OS) and leukemia-free survival (LFS) were 53.6% and 42.7%, respectively. Haplo-SCT showed inferior OS compared to MSD (HR 1.79, p = 0.003) and UD (HR 1.64, p = 0.004) and reduced chronic graft-versus-host disease. Patients with t(8;21) exhibited higher relapse incidence (HR 2.04, p = 0.002) and poorer survival outcomes than those with inv(16). These findings confirm the therapeutic role of allo-SCT in R/R CBF-AML in non-CR, supporting its favorable risk profile.

Indexed as

Core Binding FactorsHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteTransplantation ConditioningTransplantation, HomologousAdolescentAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultCore Binding Factors

Identifiers

PMID40269277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.